NCT05190445View on ClinicalTrials.gov

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions
HER2-positive Gastric Cancer
Interventions
DRUG

Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel

HER2/4-1BB

DRUG

Cinrebafusp alfa (PRS-343) in combination with tucatinib

HER2/4-1BB

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

20904

Maryland Oncology-Hematology, Silver Spring

77030

University of Texas MD Anderson Cancer Center, Houston

93105

Sansum Clinic, Santa Barbara

Unknown

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Pieris Pharmaceuticals, Inc.

INDUSTRY

NCT05190445 - Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | Biotech Hunter | Biotech Hunter